Diabetes drug empagliflozin tested in over 200,000 patients in Real-World setting

NCT ID NCT03363464

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 6 times

Summary

This study looks at how well the diabetes drug empagliflozin (Jardiance) works in everyday medical practice, outside of a controlled research setting. Researchers are comparing it to other diabetes medicines in over 230,000 adults with type 2 diabetes. The goal is to see if the heart and kidney benefits seen in earlier trials hold true for a wider range of patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (also known as Jardiance)
What this could lead to: If successful, this study could confirm that empagliflozin's heart and kidney benefits seen in clinical trials also apply to a broader, real-world population with type 2 diabetes.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by differences between patient groups. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Bringham Women Hospital

Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.